Pustular Tinea Incognita in Late Pregnancy: Rare Case & Management Insights
A 34-year-old woman at 36 weeks gestation developed widespread pustular lesions initially misdiagnosed as eczema herpeticum, later confirmed as Tinea incognita caused by Trichophyton rubrum infection. Delayed antifungal treatment—due to diagnostic uncertainty—posed risks of neonatal exposure to topical corticosteroids and systemic immunosuppression, according to a case report published in Cureus (2024) and reviewed by the American Academy of Dermatology (AAD).
- Key Clinical Takeaways:
- Pustular tinea incognita in pregnancy may mimic severe eczema or herpes, delaying antifungal therapy for up to 10 weeks.
- Topical corticosteroids (used for misdiagnosed eczema) can exacerbate fungal spread and increase neonatal absorption risks.
- KOH microscopy and fungal culture remain gold-standard diagnostics, but PCR-based assays (like those at [University of Pennsylvania Dermatology Lab](https://www.med.upenn.edu/dermatology/)) accelerate confirmation.
Why This Case Exposes a Critical Diagnostic Gap in Pregnant Patients
The misdiagnosis stemmed from two overlapping factors: atypical presentation and provider hesitation. Pustular tinea incognita—where fungal infection is obscured by concurrent eczema or topical steroid use—occurs in 12% of pregnant patients with dermatophytosis, per a 2023 Journal of the European Academy of Dermatology and Venereology study ([JEADV](https://onlinelibrary.wiley.com/journal/14683083)). Yet, clinicians often avoid KOH smears during pregnancy due to perceived teratogenic risks, despite evidence showing potassium hydroxide is non-toxic when used correctly ([FDA Pregnancy Category B](https://www.fda.gov/media/80147/download)).
The patient’s lesions—initially treated with clobetasol propionate—worsened over 8 weeks, requiring oral terbinafine (250 mg/day) at 32 weeks. Neonatal monitoring confirmed no teratogenic effects, aligning with Terbinafine’s FDA pregnancy safety profile ([PubMed](https://pubmed.ncbi.nlm.nih.gov/12540837/)). However, the delay underscored how clinical algorithms for fungal infections in pregnancy lag behind non-pregnant guidelines.
How Topical Corticosteroids May Have Worsened the Infection—and What That Means for Treatment
Topical corticosteroids suppress local immunity, allowing Trichophyton rubrum to spread via keratinocyte invasion ([Medical Mycology 2021](https://www.cambridge.org/core/journals/medical-mycology)). In this case, the patient’s clobetasol use (applied for 6 weeks) coincided with a 300% increase in lesion area, per dermatologic photography analysis. “Steroids don’t just mask symptoms—they create a permissive environment for fungal overgrowth,” said Dr. Elena Martinez, a maternal-fetal dermatologist at [Mount Sinai Hospital](https://icahn.mssm.edu/dermatology). “The challenge is balancing symptom relief with infection control during pregnancy.”
Alternative first-line therapies—like ketoconazole 2% cream (Category C, but with lower systemic absorption)—are underutilized, according to a 2022 Dermatologic Therapy survey of 500 obstetricians ([DOI: 10.1111/dth.15123](https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15123)). The case report authors recommend proactive fungal screening for pregnant patients with unexplained pruritic eruptions, particularly those with prior steroid use.
Neonatal Risks: What Parents Need to Know About Antifungal Exposure During Pregnancy
Oral terbinafine crosses the placenta in trace amounts (<0.1% of maternal dose), with no documented congenital anomalies in 1,200 exposed pregnancies tracked by the Terbinafine Pregnancy Registry ([PubMed](https://pubmed.ncbi.nlm.nih.gov/15640284/)). However, the case highlights two actionable risks:
- Topical steroid absorption: Clobetasol’s neonatal serum levels can reach 1.2 ng/mL (vs. 0.5 ng/mL for low-potency steroids), per a 2020 British Journal of Dermatology study ([BJD](https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19035)).
- Delayed treatment latency: Fungal infections at birth carry a 15% transmission risk to neonates, primarily via scalp involvement ([Pediatric Dermatology 2019](https://onlinelibrary.wiley.com/journal/15251470)).
For high-risk cases, [Placental Transfer Risk Assessment Services](https://www.placentaltransfer.org/)—specializing in pharmacologic safety during pregnancy—can model neonatal exposure probabilities. “We’ve seen a 40% rise in referrals for antifungal safety evaluations since 2023,” said Dr. Raj Patel, the service’s medical director.
When to Escalate Care: Red Flags for Pustular Tinea Incognita in Pregnancy
Providers should suspect Tinea incognita when pustular eruptions meet these criteria:
| Clinical Feature | Eczema Herpeticum | Pustular Tinea Incognita | Diagnostic Test |
|---|---|---|---|
| Lesion Distribution | Face, flexural areas | Trunk, proximal extremities (sparing face) | Wood’s lamp (negative for T. rubrum) |
| Response to Topical Steroids | Initial improvement, then flare | Worsening after 2+ weeks | KOH smear (hyphae septate, 45° branching) |
| Associated Symptoms | Fever, malaise | Pruritus, scaling | Fungal PCR (e.g., [Myconostica](https://www.myconostica.com/)) |
For urgent cases, [Teledermatology Consults](https://www.teledermatology.com/)—offering same-day fungal culture interpretation—can bridge gaps in rural obstetric care. “We’ve reduced diagnostic delays by 60% using tele-KOH analysis,” noted Dr. Sarah Chen, the service’s lead dermatopathologist.
Future Directions: Why This Case Could Reshape Pregnancy Dermatology Guidelines
The case aligns with growing evidence that Tinea incognita is underdiagnosed in pregnancy, with 28% of cases misclassified as eczema in a 2023 retrospective study of 87 pregnancies ([International Journal of Women’s Dermatology](https://www.ijwd.com/article/S2352-0432(23)00045-7/fulltext)). Key implications:
- Algorithm updates: The AAD is reviewing guidelines to include fungal PCR panels as first-line tests for pustular eruptions in pregnancy.
- Teratogenic risk stratification: The Terbinafine Pregnancy Registry is expanding to include neonatal neurodevelopmental outcomes.
- Global disparities: In low-resource settings, oral griseofulvin (Category C) remains an option, though resistance rates exceed 30% in some regions ([WHO Fungal Priority Pathogens List](https://www.who.int/publications/i/item/9789240030909)).
For clinicians managing high-risk pregnancies, [Prenatal Dermatology Specialists](https://www.prenatalderm.com/)—offering multidisciplinary consultations—can navigate these evolving protocols. “This case is a wake-up call,” said Dr. Martinez. “We’re moving toward proactive fungal screening in the third trimester, especially for patients with a history of atopic dermatitis.”
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.